A1M Pharma AB has changed its name to Guard Therapeutics International AB

Visit guardtherapeutics.com

The Board

The Board

Bild05

Cristina Glad

Chairman of the board

Member of the board since November 2012. Born in 1952. Cristina Glad holds a PhD in biochemistry and an Executive MBA. Cristina Glad has more than 25 years of research and business development experience within biotech and development of pharmaceuticals, covering diagnostic and therapeutic antibodies, development of production processes for antibody pharmaceuticals, setup of contract manufacturing operations, development of antibody pharmaceuticals, R&D cooperations with biotech and pharmaceutical companies, and in- and out-licensing of projects. In her previous role as CEO as well as vice-president, Cristina Glad was involved in evolving BioInvent International AB from a technology platform company to a company with several drug candidates in its product portfolio. She is running her own consulting business since December 2013. Cristina Glad is a member of the Royal Swedish Academy of Engineering Sciences (IVA).

Other appointments
Cristina Glad is a member of the Board of Directors of Medeon Aktiebolag, Preelumina Diagostics AB, Aptahem AB, RhoVac AB, Region Skåne Holding AB and Chairman of the Board of Laccure AB and since December 2012 has run C Glad Consulting AB, where she is the sole member of the Board. In addition to the Board assignment, Cristina Glad also holds consulting assignments for the Company.

Previous assignments in the last five years
Cristina Glad is the former CEO and vice-president of BioInvent International AB, and has also been a member of the board of BioInvent Finans AB.

Shareholding: 45,705 shares and 12,188 subscription warrants

Independent in relation to the company and its senior management as well as to its major shareholders.

Goran Forsberg 1 1

Göran Forsberg

Member of the board

Board member since May 2019. Born 1963. Göran Forsberg is a PhD in Biochemistry and Associate Professor. He has more than 30 years of experience from pharmaceutical development in both the Biotech industry and in large pharmaceutical companies. Göran Forsberg has extensive experience of many different parts of drug development, as well as business development and investor relations. Göran Forsberg has been CEO of Cantargia AB since 2014. Prior to that, he worked as a business development manager at Active Biotech. Previous experience comes from positions at Pharmacia, KabiGen and the University of Adelaide in Australia.

Other assignments: Board member of Isogenica Ltd.

Previous assignments in the last five years: -

Shareholding: 25,000 shares

Independent in relation to the company and its senior management as well as to its major shareholders.

J hulthe1

Johannes Hulthe

Member of the board

Board member since May 2019. Born 1970. Johannes Hulthe is a PhD and MSc in Economics and has more than 17 years of experience from the pharmaceutical industry. Lecturer in cardiovascular prevention at Sahlgrenska University Hospital, Gothenburg. Johannes Hulthe was under 13 years employed at AstraZeneca and, when he finished in 2014, held the role of chief (vice president) in clinical drug development for heart vessels, metabolism and kidney disease.

Other assignments: Co-founder, CEO and board member of Antaros Medical AB, board member of Antaros Holding AB, chairman of Antaros Renostic AB.

Shareholding: -

Independent in relation to the company and its senior management as well as to its major shareholders.